Medicine Press release

Eisai Co., Ltd. and EcoNaviSta Inc. announced today that they have entered into a business alliance agreement and commenced collaboration with the aim of building an ecosystem in the area of dementia, which is a pressing matter in Japan's super-aging society.
More info..

The conference will be held in Philadelphia and virtually from July 28 to August 1, 2024. Eisai will present data and research in four (4) oral and 15 poster presentations at the meeting and will host two (2) sessions on lecanemab.
More info..

VitalLife Scientific Wellness Center, a subsidiary of Bumrungrad International Hospital in Bangkok, Thailand, recognized as one of Newsweek's World's Best Hospitals for four consecutive years (2021-2024), and NEC Corporation, a leader in IT, network and AI technologies, have announced the introduction of NEC's FonesVisuas Test in Thailand.
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (generic name: lecanemab) has been approved in Israel as a treatment of Alzheimer's disease (AD).
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated amyloid-beta (Abeta;) monoclonal antibody "LEQEMBI" (brand name in Hong Kong: generic name: lecanemab) for treatment of Alzheimer's disease (AD).
More info..

Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), formerly known as MORAb-202, a folate receptor alpha (FRα)-targeting antibody drug conjugate (ADC) due to ongoing portfolio prioritization efforts within Bristol Myers Squibb.
More info..

China is the third country to launch LEQEMBI following the United States and Japan.
More info..

Eisai Co., Ltd. announced today that the company has achieved the pre-set performance indicators in FY2023 for the dementia examination project in Bunkyo City, Tokyo, which the company has been commissioned to conduct in order to raise awareness of dementia and promote early detection, and will continue the commission for this project in FY2024.
More info..

Fujitsu Japan Limited and Kamoenai Village in Hokkaido today announced the start of an initiative to promote awareness in dental care.
More info..

Olympus Corporation (Olympus), a global MedTech Company committed to making people's lives healthier, safer and more fulfilling, today announced its strategic initiative to establish an R&D Offshore Development Center (ODC) in Hyderabad, India.
More info..